Assuming multiple is required, the following results were found.

  • Boster's Corner: Multiple Sclerosis Vlog: SUPPLEMENTS FOR MS? Vitamin D3 and much more

    Aaron Boster MD September 2019 Supplements for Multiple Sclerosis? In this video I teach you about nutrition & dietary supplements for MS. Got Vitamin D3? If you want to up your food game, start watching this video! Content was originally recorded...

    https://mschristian.org/index.php/articles/2-uncategorised/8786-boster-s-corner-multiple-sclerosis-vlog-supplements-for-ms-vitamin-d3-and-much-more
  • Economic Factors Amplify Burden of Disease for Patients With Multiple Sclerosis

    Sept 2019 While economic issues differ across countries and healthcare systems, a universal concern is that multiple sclerosis (MS) is a costly disease that exerts a significant burden on patients, families, and society as a whole. Speaking at the...

    https://mschristian.org/index.php/articles/2-uncategorised/8610-economic-factors-amplify-burden-of-disease-for-patients-with-multiple-sclerosis
  • J.K. Rowling Gives $18M to Multiple Sclerosis Research - TIME

    (LONDON) — Harry Potter author J.K. Rowling has made a substantial donation for research into the treatment of multiple sclerosis at a center named after her late mother. The 15.3 million-pound ($18.8 million) donation announced Thursday will be used...

    https://mschristian.org/index.php/articles/2-uncategorised/8607-j-k-rowling-gives-18m-to-multiple-sclerosis-research-time
  • Fast Five Quiz: Secondary Progressive Multiple Sclerosis - Medscape

    Multiple sclerosis (MS) is a chronic, immune-mediated inflammatory disease that attacks the myelin of the central nervous system. The most common type is relapsing-remitting multiple sclerosis (RRMS), which accounts for approximately 85% of MS cases...

    https://mschristian.org/index.php/blog/fast-five-quiz-secondary-progressive-multiple-sclerosis-medscape
  • A Cheap Biotech Stock Tests a Novel Treatment for Multiple Sclerosis - Barron's

    Atara Biotherapeutics has an out-of-favor stock and a novel treatment for multiple sclerosis that’s in early clinical trials. At an international meeting of MS doctors on Friday, researchers reported that Atara’s therapy showed hints of actually...

    https://mschristian.org/index.php/blog/a-cheap-biotech-stock-tests-a-novel-treatment-for-multiple-sclerosis-barron-s
  • Study investigates link between social cognition and fatigue, mood in multiple sclerosis

    B.Sc. (Editor)Aug 29 2019 A recent study by Kessler Foundation researchers linked the deficits in social cognition in multiple sclerosis with symptoms in other domains. The article, "Relationship between social cognition and fatigue, depressive...

    https://mschristian.org/index.php/blog/study-investigates-link-between-social-cognition-and-fatigue-mood-in-multiple-sclerosis
  • How the gut influences neurologic disease

    crosstalk between immune cells and brain cells. Their new publication defines a pathway that may help guide therapies for multiple sclerosis and other neurologic diseases. "These findings provide a clear understanding of how the gut impacts central...

    https://mschristian.org/index.php/blog/how-the-gut-influences-neurologic-disease
  • Biogen Strengthens MS & SMA Portfolio as Competition Lurks - Yahoo Finance

    Biogen, Inc. BIIB has a strong position in the multiple sclerosis (MS) market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. It is working on strengthening its position further by bringing new treatments. In November...

    https://mschristian.org/index.php/blog/biogen-strengthens-ms-sma-portfolio-as-competition-lurks-yahoo-finance
  • Studies Report on Efforts to Optimize Rituximab in MS, NMOSD - The Center for Biosimilars

    While rituximab does not carry indications for the treatment of multiple sclerosis (MS) or aquaporin-4-positive (AQP4) neuromyelitis optica spectrum disorder (NMOSD), the CD20-depleting therapy and its biosimilars are commonly used off-label, as the...

    https://mschristian.org/index.php/blog/studies-report-on-efforts-to-optimize-rituximab-in-ms-nmosd-the-center-for-biosimilars
  • AJMC® in the Press, September 13, 2019 - AJMC.com Managed Markets Network

    test results had increased adherence and overall cost savings. AJMC®’s video series “Identifying Secondary Progressive Multiple Sclerosis” was highlighted by Multiple Sclerosis News Today. The video series, which features multiple key opinion leaders,...

    https://mschristian.org/index.php/blog/ajmc-in-the-press-september-13-2019-ajmc-com-managed-markets-network
  • What to know about surgery for MS

    Table of contents Multiple sclerosis attacks the protective coating around the nerves throughout the body, including those in the brain. Multiple sclerosis is a progressive disease, which means that it typically becomes worse over time. As it...

    https://mschristian.org/index.php/blog/what-to-know-about-surgery-for-ms-1
  • Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.

    M5. Author information Abstract BACKGROUND: A consensus of early treatment with disease-modifying therapies (DMT) in multiple sclerosis (MS) has been reached based on several observational and experimental studies in adults. However, paediatric onset...

    https://mschristian.org/index.php/articles/2-uncategorised/9972-long-term-effect-of-delayed-treatment-on-disability-in-patients-with-paediatric-onset-multiple-sclerosis-a-prospective-danish-cohort-study
  • New discovery provides hope for improved multiple sclerosis therapies - Medical Xpress

    College Dublin have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS) and other autoimmune diseases such as psoriasis and rheumatoid arthritis. Their work highlights the significant...

    https://mschristian.org/index.php/articles/2-uncategorised/9956-new-discovery-provides-hope-for-improved-multiple-sclerosis-therapies-medical-xpress
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    studies, ofatumumab demonstrated superiority over Aubagio®* (teriflunomide) in patients with relapsing forms of multiple sclerosis (RMS)[1]. The ASCLEPIOS studies investigated the efficacy and safety of monthly subcutaneous ofatumumab 20mg versus once...

    https://mschristian.org/index.php/articles/2-uncategorised/8790-novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies-1
  • Novartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studies

    studies, ofatumumab demonstrated superiority over Aubagio®* (teriflunomide) in patients with relapsing forms of multiple sclerosis (RMS)[1]. The ASCLEPIOS studies investigated the efficacy and safety of monthly subcutaneous ofatumumab 20mg versus once...

    https://mschristian.org/index.php/articles/2-uncategorised/8616-novartis-ofatumumab-demonstrates-superiority-versus-aubagio-in-two-head-to-head-phase-iii-multiple-sclerosis-studies
  • Genentech Presents New Six-Year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation and Continuation of Treatment Reduced Disability Progression in Multiple Sclerosis

    benefit-risk profile. Findings were presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Stockholm. “The effect of MS therapies on progression – not just relapses – is very important to...

    https://mschristian.org/index.php/articles/2-uncategorised/8611-genentech-presents-new-six-year-ocrevus-ocrelizumab-data-which-showed-that-earlier-initiation-and-continuation-of-treatment-reduced-disability-progression-in-multiple-sclerosis
  • Mechanism controlling multiple sclerosis risk identified

    individuals. Researchers at Karolinska Institutet in Sweden have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant...

    https://mschristian.org/index.php/articles/2-uncategorised/4201-mechanism-controlling-multiple-sclerosis-risk-identified
  • Coronavirus and MS Reporting Database Announced by Consortium of Multiple Sclerosis Centers & National Multiple Sclerosis Society

    Coronavirus and MS Reporting Database Announced by Consortium of Multiple Sclerosis Centers & National Multiple Sclerosis Society Click HERE to Register for the MS Beacon Newsletter COVID-19 – WHAT HAVE WE LEARNED SO FAR? Authors: Katrina Mountfort,...

    https://mschristian.org/index.php/blog/coronavirus-and-ms-reporting-database-announced-by-consortium-of-multiple-sclerosis-centers-national-multiple-sclerosis-society
  • How new gene discoveries could guide precision medicine in multiple sclerosis

    by Arlene Weintraub | Oct 31, 2019 10:20am Variants in three "complement" genes are closely associated with vision loss in multiple sclerosis, Johns Hopkins Medicine researchers discovered. (Pixabay) The most severe form of multiple sclerosis, called...

    https://mschristian.org/index.php/blog/how-new-gene-discoveries-could-guide-precision-medicine-in-multiple-sclerosis
  • Multiple sclerosis drug slows brain shrinkage, study finds

    Results from a clinical trial of more than 250 participants with progressive multiple sclerosis (MS) revealed that ibudilast was better than a placebo in slowing down brain shrinkage. The study also showed that the main side effects of ibudilast were...

    https://mschristian.org/index.php/blog/multiple-sclerosis-drug-slows-brain-shrinkage-study-finds

Results 141 - 160 of 713